We used gene expression profiling to establish a molecular diagnosis of mantle cell lymphoma (MCL), to elucidate its pathogenesis, and to predict the length of survival of these patients. An MCL gene expression signature defined a large subset of MCLs that expressed cyclin D1 and a novel subset that lacked cyclin D1 expression. A precise measurement of tumor cell proliferation, provided by the expression of proliferation signature genes, identified patient subsets that differed by more than 5 years in median survival. Differences in cyclin D1 mRNA abundance synergized with INK4a/ARF locus deletions to dictate tumor proliferation rate and survival. We propose a quantitative model of the aberrant cell cycle regulation in MCL that provides a rationale for the design of cell cycle inhibitor therapy in this malignancy.
Introduction
cal review. Since the t(11;14) translocation and cyclin D1 overexpression have been consistently associated with MCL, we measured cyclin D1 mRNA levels in each potential MCL case by Mantle cell lymphoma (MCL) was originally identified as a morphologically distinct subtype of non-Hodgkin's lymphoma, and quantitative RT-PCR. Of the 101 cases with MCL histology, 92 expressed cyclin D1 mRNA, and these were considered the subsequently the t(11;14) translocation was defined as a characteristic molecular feature of this lymphoma subtype (Campo et "core" group of bona fide MCLs. We used Lymphochip DNA microarrays (Alizadeh et al., 1999) to profile gene expression in al Raffeld and Jaffe, 1991; Swerdlow and Williams, 2002; Weisenburger and Armitage, 1996) . This translocation leads to all 101 lymphoma cases with MCL morphology. For comparison, we profiled gene expression in 20 cases of SLL and used preoverexpression of cyclin D1, a D-type cyclin that is not usually expressed at high levels in normal B lymphocytes (Rosenberg viously published gene expression data from two subgroups of diffuse large B cell lymphoma (DLBCL), germinal center B cellet al., 1991) . Current WHO guidelines for the diagnosis of MCL rely on morphological assessment supplemented with analysis like (GCB) DLBCL (134 cases), and activated B cell-like (ABC) DLBCL (83 cases) (Rosenwald et al., 2002) . Several thousand of cyclin D1 translocation or overexpression . Cyclin D1 translocation and expression has been helpful in disgenes were differentially expressed between MCL and the other lymphoma subtypes with high statistical significance (p Ͻ tinguishing MCL from other chronic B cell malignancies, such as small lymphocytic lymphoma/chronic lymphocytic leukemia 0.001), and those "MCL signature genes" that were most highly and differentially expressed in MCL are shown in Figure 1A (a (SLL/CLL), follicular lymphoma, and marginal zone lymphoma. Nevertheless, some lymphomas that lack cyclin D1 expression complete listing of these genes is available at http://llmpp.nih. gov/MCL). are morphologically similar to MCL and may be variant forms of this lymphoma type (Yatabe et al., 2000) .
To create a gene expression-based diagnostic test for MCL, we developed a Bayesian statistical method that was able to MCL accounts for 6% of all non-Hodgkin's lymphomas and a higher fraction of deaths from lymphoma, given that it is an distinguish MCL from other lymphoma subtypes. In brief, we began by identifying the most differentially expressed genes incurable malignancy (Campo et al., 1999; Swerdlow and Williams, 2002; TNHLCP, 1997) . The length of survival of MCL between cyclin D1-positive MCL and each of the other lymphoma types. These differentially expressed genes were compatients following diagnosis is quite variable. The median survival in MCL is approximately 3 years, but some patients have bined to form a series of binary predictors that estimated the probability that a particular lymphoma sample was MCL or one an aggressive disease to which they succumb in less than 1 year. Other patients have a comparatively indolent disease, and of the other lymphoma types. We used a cutoff of 90% probability in assigning a sample to a lymphoma type based on these some patients may survive more than 10 years.
Faced with this clinical heterogeneity, many attempts have binary predictors. To insure the reproducibility of our method, we divided the been made to develop prognostic markers of survival. Several morphological subtypes of MCL have been recognized, and a cyclin D1-positive MCL cases into two equal groups: a "training set" that was used to develop the MCL diagnostic test, and a blastic variant of MCL has been associated with short survival in several studies (Argatoff et al., 1997; Bosch et al., 1998;  "validation set" that was used to evaluate the test. We optimized the number of genes in each binary lymphoma type predictor Lardelli et al., 1990) . High tumor cell proliferation has also been associated with shorter survival (Argatoff et al., 1997; so as to minimize the number of classification errors when the predictor was applied to the training set cases in a crossvalidaal., 1998; Raty et al., 2002; Velders et al., 1996) , as has INK4a/ ARF locus deletion (Dreyling et al., 1997; Pinyol et al., 1998) tion, leave-one-out fashion. We deliberately excluded cyclin D1 as a lymphoma type distinction gene because we wished to and p53 mutation or protein overexpression (Greiner et al., 1996; Hernandez et al., 1996; Louie et al., 1995) . However, the progapply our model to potential MCL cases that were cyclin D1-negative. Using the optimized lymphoma type predictors, 100% nostic groups defined by each of these markers were still clinically heterogeneous, demonstrating that each marker alone of the training set cases were correctly classified ( Figure 1B ). When applied to the validation set, the model correctly classified does not fully account for the clinical behavior of these tumors.
In the present study, our first goal was to establish a molecu-98% of the cyclin D1-positive MCL cases as MCL, thus establishing this method as a reliable MCL diagnostic test ( Figure 1B ). lar diagnosis of MCL based on gene expression that could reliably distinguish this disease from other lymphoma types.
We applied this MCL diagnostic test to 9 lymphoma cases that were morphologically consistent with MCL but were negaWith such a diagnostic test in hand, we investigated which genes had expression patterns that correlated with length of tive for cyclin D1 expression by quantitative RT-PCR analysis. Seven were classified as MCL, one was classified as GCB survival. We show that genes involved in proliferation have an DLBCL, and one was not assigned to any lymphoma group overriding influence on the clinical course and can be used based on the probability cutoff used. As shown in Figure 1C , to construct a powerful predictor of survival. Additionally, we the 7 cyclin D1-negative MCL tumors were comparable to cyclin demonstrate that the proliferation signature integrates several D1-positive MCL tumors with respect to expression of 42 MCL oncogenic mechanisms in MCL that govern the cell cycle, leadsignature genes. Interestingly, 2 of these cyclin D1-negative ing us to propose a quantitative model for MCL pathogenesis.
tumors expressed higher levels of cyclin D3, and 1 expressed higher levels of cyclin D2 than were detected in cyclin D1-Results positive MCLs. At present, the molecular mechanisms underlying the expression of other D-type cyclins in these cases are Molecular diagnosis of MCL To establish a molecular diagnosis of MCL based on gene exunclear, but this finding suggests that these tumors may have found alternative ways to increase cell cycle progression in the pression, we began by identifying lymphoma cases that were morphologically consistent with this diagnosis upon pathologiabsence of cyclin D1. Overall survival of patients with cyclin D1-positive MCL was not statistically different from that of paTo visualize the predictive power of our survival model, we ranked the patients according to the expression of the proliferatients with cyclin D1-negative MCL ( Figure 1D ). tion signature genes in their tumors, and divided them into 4 equal quartiles. Figure 2B shows Kaplan-Meier plots of overall A gene expression-based predictor of survival We next used gene expression to develop a predictor of length survival of patients in each of these quartiles, within the training set, the validation set, and the total set of cases. These plots of survival following diagnosis of MCL. The median survival of the patients with cyclin D1-positive MCL was 2.8 years, but the indicate that the proliferation signature can identify patient subsets with strikingly different survival times. The median survival lengths of survival were quite heterogeneous ( Figure 1D ). Many patients died within the first 2 years following diagnosis, yet times of patients in the four quartiles were: 6.71 years (quartile 1), 3.28 years (quartile 2), 2.31 years (quartile 3), and 0.83 years 15% (14/92) of the patients survived more than 5 years and 3 patients survived more than 10 years. It is important to empha-(quartile 4). It is important to emphasize that the quartile method that we used to group MCL patients is merely a way of illustrating size that the diagnosis of MCL in these patients was based on morphology, cyclin D1 expression, and expression of genes the quantitative relationship between proliferation and survival. The proliferation signature average is a continuous variable that that distinguish MCL from other non-Hodgkin's lymphomas. Thus, the differences in survival among these patients are unassigns, for each patient, a discrete probability of survival at every time point following diagnosis. The proliferation signature likely to be due to the inadvertent inclusion of other lymphoma types in our cohort.
average varied over a 13.5-fold range and a 2-fold increase in the proliferation signature average corresponded to a 3.6-fold We used a supervised approach to discover "survival prediction" genes with expression patterns that were associated with increased relative risk of dying. Several histological subtypes of MCL can be discerned, and length of survival among MCL patients in the training sets. The expression levels of 48 genes correlated with survival with high these have been shown to differ with respect to proliferation rate and survival (Argatoff et al., 1997; Bosch et al., 1998) . statistical significance (p Ͻ 0.001), and all of these were more highly expressed in tumors from patients with short survival.
We subdivided our MCL cases by morphology into classical (68.4%), blastic (9.8%), pleomorphic (6.5%), and small cell As in our previous analysis of survival of patients with DLBCL (Rosenwald et al., 2002) , we functionally classified the survival (9.8%) subtypes. As expected, the cases with blastic morphology had the highest expression of the proliferation signature prediction genes based on their membership in gene expression "signatures." A gene expression signature is a group of genes ( Figure 3A ) and the shortest survival ( Figure 3B ). However, the morphological categorization of MCL was a much weaker prethat are coordinately expressed in association with a particular biological process (Shaffer et al., 2001) . Notably, 58% of the dictor of survival (p ϭ 5.7 ϫ 10 Ϫ3 ) than was the proliferation signature. survival prediction genes (28/48) belonged to the proliferation gene expression signature. This signature is composed of genes that are expressed at higher levels in dividing cells than in quies-
The proliferation signature integrates oncogenic events associated with survival cent cells, including genes required for DNA replication, cell cycle progression, and the metabolic demands of proliferation Having related the proliferation signature to overall survival in MCL, we searched for molecular mechanisms that might explain (Shaffer et al., 2001) . We further focused our attention on those survival prediction genes that were most variably expressed the variable proliferation of MCLs. We noted that the mRNA expression of the cyclin D1 coding region, as measured by a among the MCLs (i.e., in the top third of gene expression variance) in order to facilitate the subsequent analysis of these quantitative RT-PCR assay, was higher in more proliferative MCLs (p ϭ 1.4 ϫ 10 Ϫ4 ; Figure 4A ). Further, the abundance of genes by other methodologies; 34 genes satisfied this selection criterion, of which 20 belonged to the proliferation signature. cyclin D1 coding region mRNA was a univariate predictor of survival (p ϭ 4.69 ϫ 10 Ϫ4 ), but was not as strong a prognostic We averaged the expression levels of these 20 genes to create a proliferation signature average for each MCL case. Tumor cell marker as the proliferation signature ( Figure 4E ). The expression of cyclin D1 coding region mRNA was correlated with proliferaproliferation rate can also be estimated by the number of Ki67-positive cells or by the mitotic index, and these data were availtion (p ϭ 1.4 ϫ 10 Ϫ4 ), and therefore did not add to the prognostic strength of the proliferation signature in a 2-component model. able on 14 patients. As expected, the proliferation signature average was correlated with the number of Ki67-positive cells These results suggests a direct relationship between cyclin D1 expression levels and proliferation rate in MCL, and demonstrate (r ϭ 0.69) and the mitotic index (r ϭ 0.62).
Within the training set, the proliferation signature average that the length of survival of MCL patients depends upon quantitative differences in progression from G1 to S phase of the cell was inversely correlated with survival with high statistical significance (1.92 ϫ 10 Ϫ5 ). Importantly, the proliferation signature cycle. MCLs can express various cyclin D1 mRNA isoforms that average also predicted survival of patients in the validation set with high significance (7.44 ϫ 10 Ϫ5 ), thus demonstrating the all include the cyclin D1 coding region but that differ in the length of their 3Ј untranslated regions (UTRs) ( Figure 4G ). The reproducibility of this gene expression-based predictor. When all cases were considered together, this predictor correlated with 4.5 kb mRNA isoform has an extended UTR that includes an AT-rich segment with the potential to decrease mRNA stability survival with a significance of p ϭ 5.07 ϫ 10 Ϫ9 . None of the other survival prediction genes from the original set of 48 improved (Lebwohl et al., 1994; Lin et al., 2000; Rimokh et al., 1994) . Some MCLs have alterations in the cyclin D1 genomic sequences that the prognostic ability of the proliferation signature average in multivariate models. Of note, we could also construct a model encode the 3Ј UTR region, and these cases do not express the 4.5 kb mRNA isoform, but instead express a 1.7 kb mRNA from only 4 proliferation signature genes (CDC2, ASPM, tubulin ␣, CENP-F) that predicted length of survival with high statistical isoform or other short mRNAs that lack the potential mRNA destabilizing element in the 3Ј UTR (Bosch et al., 1994 ; de Boer significance on the total set of cases (p ϭ 2.67 ϫ 10 Ϫ8 ). Rimokh et al., 1994; Seto et al., 1992; Withers et With some MCL samples, we obtained little if any signal from the cyclin D1 3Ј UTR features on the microarray, yet these al., 1991). On the Lymphochip DNA microarray, the cyclin D1 features correspond to the extended 3Ј UTR, and therefore can same samples had abundant expression of the cyclin D1 coding region as assessed by the quantitative RT-PCR assay (Figure only detect expression of the 4.5 kb mRNA. In contrast, the quantitative RT-PCR assay for the cyclin D1 coding region can 4A). This pattern suggests that these MCL tumors preferentially express the short cyclin D1 mRNA isoforms lacking the exdetect shorter isoforms lacking the extended 3Ј UTR as well as the 4.5 kb isoform. tended 3Ј UTR. Notably, the MCLs with this expression pattern were generally among those with high proliferation ( Figure 4A ). tical model of survival, such that the combined model had a greater significance (p ϭ 3.59 ϫ 10 Ϫ6 ) than models of survival Based on levels of cyclin D1 3Ј UTR expression, we defined a "3Ј UTR low" group of 17 MCL cases and a "3Ј UTR high" group based on either of these components alone ( Figure 5C ). Deletional events at the p53 and ATM loci had distinct but of 75 MCL cases ( Figure 4B ). The 3Ј UTR low group had a 1.58-fold higher level of cyclin D1 coding region mRNA than did the overlapping distributions with respect to each other and with respect to INK4a/ARF locus deletions ( Figure 5A ). p53 deletions 3Ј UTR high group (p ϭ 5.4 ϫ 10 Ϫ5 ), thus providing one potential molecular mechanism for the variable expression of cyclin D1
were found in 9 MCL cases (11%), and concurrent deletions of INK4a/ARF locus and ATM were found in 3 and 6 cases, coding region mRNAs ( Figure 4C ). Further, the 3Ј UTR low group had a 1.83-fold higher expression of the proliferation signature respectively. ATM deletions were more frequent among the MCLs, occurring in 30 cases (35%), and were concurrent with (p ϭ 1.3 ϫ 10 Ϫ7 ; Figure 4D ) and a shorter survival than the 3Ј UTR high group (p ϭ 7.97 ϫ 10 Ϫ5 ; Figure 4F ).
INK4a/ARF locus and p53 deletions in 8 and 6 cases, respectively. These findings suggest that loss of these tumor suppresWe next investigated whether deletions of tumor suppressor genes were associated with proliferation rate and survival in sor genes provided nonredundant selective advantages to the MCLs during the natural histories of these lymphomas. p53 MCL. We used a quantitative PCR assay to detect genomic loss of one or both alleles of the INK4a/ARF locus, which endeletions were not strongly associated with proliferation ( Figure  5A ) or survival (p ϭ 0.25; data not shown), although the number codes two tumor suppressors, p16
INK4a and p14 ARF . INK4a/ARF locus deletions were detected in 21% (18/85) of the cases and of p53 deletional events in our series was small, and some MCL cases may have mutations of p53 without deletion. ATM were preferentially observed among the more proliferative MCLs ( Figure 5A ). The INK4a/ARF locus can also be transcriptionally deletions were present in tumors with both low and high proliferation rates ( Figure 5A ), and had no apparent relationship to silenced by the polycomb family protein BMI-1 (Jacobs et al., 1999) , and BMI-1 is amplified and/or overexpressed in some survival (p ϭ 0.66; data not shown). MCLs (Bea et al., 2001) . Notably, BMI-1 was overexpressed in some highly proliferative MCLs that lacked INK4a/ARF locus Discussion deletion ( Figure 5A ).
We next tested whether the proliferation rate of MCL tumors We have taken a quantitative approach to understand the pathogenesis of MCL and to account for the variable survival of these could be modeled using a combination of the INK4a/ARF locus deletional status and the expression of cyclin D1 coding region patients. By precisely measuring the expression of genes associated with proliferation, we found that the degree of tumor cell mRNA. Both of these parameters added independently to a model of survival: cyclin D1 coding region expression added to proliferation provides a powerful predictor of survival for this lymphoma. Further, our approach provides a quantitative rather the significance of a model based on INK4a/ARF locus deletion alone (p ϭ 2.6 ϫ 10 Ϫ3 ), and INK4a/ARF locus deletion added than qualitative framework for the molecular pathogenesis of this disease, in which higher cyclin D1 mRNA levels are reflected to the significance of a model based on cyclin D1 coding region expression alone (p ϭ 3.6 ϫ 10 Ϫ5 ). This finding suggests that in higher tumor cell proliferation and shorter survival. The defining oncogenic event in most MCLs is translocation increased cyclin D1 expression and INK4a/ARF locus deletion cooperate mechanistically to increase the proliferation rate (see and overexpression of cyclin D1, and this shared pathogenetic feature was central to the success of our quantitative approach. Discussion). INK4a/ARF locus deletions were also associated with shorter survival (p ϭ 4.88 ϫ 10 Ϫ4 ; Figure 5B ). Again, INK4a/ Using an RT-PCR assay, we defined a cohort of patients whose tumors expressed cyclin D1 and found that they also expressed ARF locus deletional status and cyclin D1 coding region expression added independent predictive power to a combined statisa set of MCL signature genes that distinguished this lymphoma expression is depicted over a 9-fold range, whereas the proliferation signature expression is depicted over a 4-fold range. B: Histogram of cyclin D1 3Ј UTR levels. Shown is a cutpoint that divides the MCL cases into a "3Ј UTR low" group (17 cases) and a "3Ј UTR high" group (75 cases). C: Level of cyclin D1 coding region mRNA in the "3Ј UTR low" and "3Ј UTR high" groups of MCL. The dots represent the mean value within each class, and the bars represent the standard error of that mean estimate. D: Proliferation signature averages of MCL cases in the "3Ј UTR low" and "3Ј UTR high" groups of MCL. The dots represent the mean value within each class, and the bars represent the standard error of that mean estimate. E: Kaplan-Meier estimates of overall survival according to the level of cyclin D1 coding region mRNA expression. F: Kaplan-Meier plot of overall survival according to cyclin D1 3ЈUTR expression. G: The cyclin D1 locus: alternative 3Ј polyadenylation sites can result in the expression of a short (1.7 kb) and a long (4.5 kb) cyclin D1 mRNA. type from others. By basing our molecular diagnosis on the proliferation in MCL relied on semiquantitative methods such as the mitotic index or immunohistochemical staining for Ki67 expression of cyclin D1 and the MCL signature genes, we could be confident that we were studying patients with highly related to define patient groups that differed in survival by only 2.1-2.7 years (Argatoff et al., 1997; Bosch et al., 1998; Raty et al., 2002 ; cancers, which is critical when searching for the molecular determinants of survival. Velders et al., 1996) . Since our quantitative method accounts more fully for the The MCL gene expression signature further allowed us to identify a new subtype of MCL that is cyclin D1-negative. The varying survival of MCL patients, it could prove useful in the clinical management of these patients. Since the proliferation existence of cyclin D1-negative MCL has been controversial, since other methods of detecting cyclin D1 translocations or signature can be faithfully represented by as few as 4 genes, a limited set of quantitative RT-PCR assays could be used to expression vary in sensitivity, and since other lymphoid malignancies can express cyclin D1. We identified a group of lymphoassess tumor proliferation rate. In particular, we suggest that clinical trials in MCL should incorporate a quantitative measure mas that were not only morphologically indistinguishable from cyclin D1-positive MCLs, but also shared expression of MCL of tumor proliferation rate. This would enable a direct comparison of the patients enrolled in different clinical trials and would signature genes. These patients with cyclin D1-negative MCL did not differ significantly in survival from patients with cyclin provide a rational basis by which to compare trial results. Various intensified treatments are being evaluated in MCL, D1-positive MCL. Interestingly, some of the cyclin D1-negative MCLs expressed either cyclin D2 or D3, suggesting that these including autologous and allogeneic bone marrow transplantation, modified chemotherapeutic regimens, and radioimmunocyclins can functionally substitute for cyclin D1 in MCL. At present, we do not know whether the expression of the other D-type therapy (Barista et al., 2001; Gopal et al., 2002; Leonard et al., 2001 ). Our results suggest that it may be beneficial to stratify cyclins in these cases is due to genomic rearrangements of these genes or to increased transcription. Given the importance patients for entry into clinical trials of these regimens according to the expression of proliferation signature genes in their tumors. of the G1/S phase transition in MCL, it is highly likely that all of the cyclin D1-negative MCL tumors have acquired some Clinical trials of intensified regimens might be designed to enroll only those patients whose tumor proliferation rate predicts an mechanism to accelerate entry into S phase.
Among patients with cyclin D1-positive MCL, the proliferaexceedingly short survival. Intensified regimens may not be appropriate for patients whose tumor proliferation rate predicts a tion signature was the sole gene expression feature that was significantly associated with survival. Using the proliferation siglonger survival, since these regimens may not prolong the survival of these patients and may unnecessarily expose them nature average as a metric, we identified one quartile of MCL patients who had a median survival of 6.7 years, which is excepto treatment-related toxicities. Rather, these patients could be managed conservatively, with relatively nontoxic therapies given tionally long for this incurable malignancy. At the other end of the spectrum, we identified a quartile of patients who had only as clinically indicated. In addition to its value in prognosis, the proliferation signaparticularly aggressive tumors and a median survival of only 0.8 years. This 5.9-year difference in survival highlights the potential ture proved very useful in establishing a quantitative model of MCL pathogenesis. In particular, the proliferation signature value of the proliferation gene expression signature as a prognostic test in MCL. By contrast, previous analyses of tumor cell quantitatively integrated the effects of cyclin D1 expression and deletion of the INK4a/ARF locus. However, our statistical model D1 kinase complexes. Our data demonstrate that small changes in the expression of D-type cyclins can have significant effects based on cyclin D1 expression and INK4a/ARF deletions accounted for only 32% of the variation in the proliferation signaon tumor cell proliferation and the clinical course of cancer patients. ture average (data not shown), and therefore the proliferation signature may also reflect additional oncogenic events that are High expression of the proliferation signature in MCL was also associated with deletion of the INK4a/ARF locus. This locus as yet unknown.
Higher expression of cyclin D1 mRNA was correlated with encodes two structurally unrelated tumor suppressors, p16
INK4a and p14 ARF (Sherr and McCormick, 2002) , and deletions of this increased proliferation and decreased survival time. The importance of this oncogenic mechanism in MCL has been overlooked genomic region in MCL typically inactivate both the p16 INK4a and p14 ARF genes and are frequently homozygous (Dreyling et al., since previous studies have used only semiquantitative methods to assess cyclin D1 expression and tumor proliferation. We 1997; Pinyol et al., 1997 Pinyol et al., , 1998 Pinyol et al., , 2000 . Further, the p16 INK4a gene does not sustain point mutations in MCLs as it does in melanoma noted that many of the highly proliferative MCL tumors expressed mRNA species that contained the cyclin D1 coding and other cancers (Pinyol et al., 1997 (Pinyol et al., , 2000 . Finally, we and others (Bea et al., 2001 ) observed overexpression of the BMI-1 region but not the extended 3Ј UTR region, and this was associated with higher levels of cyclin D1 coding region expression.
gene in MCLs that lacked deletion of the INK4a/ARF locus, which is notable since BMI-1 represses transcription of both MCLs and other cancers have been shown to variably express cyclin D1 mRNA isoforms that differ in the length of their 3Ј p16 INK4a and p14 ARF (Sherr and McCormick, 2002) . These considerations suggest that the INK4a/ARF deletions in MCL may be UTRs. The extended 3Ј UTR of the 4.5 kb cyclin D1 isoform contains AT-rich sequences that can modulate the stability of selected to circumvent the actions of both p16 INK4a and p14
INK4a regulates the G1/S phase transition by forming bithe mRNA, and short cyclin D1 mRNA isoforms lacking this region are more stable (Lebwohl et al., 1994; Lin et al., 2000;  nary complexes with cdk4 and cdk6, thereby preventing these subunits from associating with molecular chaperones that pro- Rimokh et al., 1994) . In some MCLs, the genomic region corresponding to the extended 3Ј UTR is deleted or rearranged, and mote their association with D-type cyclins (reviewed in Sherr and McCormick, 2002) . p16 INK4a deletion and increased cyclin these cases lack expression of the 4.5 kb mRNA isoform (de Boer et al., 1995; Rimokh et al., 1994; Seto et al., 1992 ; Withers D1 expression may therefore promote the G1/S phase transition by the same mechanism. Nonetheless, our statistical models et al., 1991). However, in some cells, the 4.5 and 1.7 kb isoforms coexist, and their relative abundance may be regulated by alterdemonstrated that cyclin D1 expression and INK4a/ARF deletions cooperated to quantitatively increase proliferation and native polyadenylation and cleavage (Xiong et al., 1991) . Regardless of the mechanism, our data demonstrate that selective shorten survival. One model to account for this oncogenic synergism would propose that the presence of wild-type levels of expression of short cyclin D1 mRNA isoforms is a pathogenetic mechanism that is associated with increased cyclin D1 expresp16 INK4a blunts the effect of increased cyclin D1 expression by preventing cyclin D1 from forming active kinase complexes. sion, more rapid proliferation, and shorter survival.
The relationship between increased cyclin D1 expression Although many cancer types have disruption in only one component of the Rb pathway (Sherr and McCormick, 2002) , our results and increased proliferation suggests a quantitative model for the G1/S phase transition. In this model, an increase in the suggest that some cancers may accumulate multiple oncogenic lesions that cooperate to quantitatively interfere with this pathintracellular concentration of cyclin D1 promotes its assembly into active kinase complexes with cdk4 and cdk6 (cyclin D1/ way and promote proliferation. Studies of mouse strains with selective disruption of the cdk4[6]), which would enhance the frequency at which the cell enters S phase by two mechanisms (reviewed in Sherr and p14 ARF gene demonstrate that p14 ARF also regulates proliferation. p14 ARF -deficient mouse embryo fibroblasts and pre-B cells diMcCormick, 2002) . Cyclin D1/cdk4(6) kinases phosphorylate the retinoblastoma (Rb) gene product and thereby promote the vide more rapidly than their wild-type counterparts and fail to senesce during repeated passaging in vitro (Kamijo et al., 1998 ; release of E2F transcription factors that are required in S phase. Further, cyclin D1/cdk4(6) complexes interact with the cyclin- Randle et al., 2001) . Further, in transgenic mice overexpressing c-myc, p14 ARF -deficiency accelerates lymphoma formation and dependent kinase inhibitors p21 and p27kip1 and titrate these factors away from cyclin E/cdk2 kinase complexes. Whereas the proliferation rate of the malignant B cells ex vivo (Eischen et al., 1999; Schmitt et al., 2002) . Although the mechanisms p21 and p27kip1 are potent inhibitors of cyclinE/cdk2, they fail to inhibit cyclin D1/cdk4(6). Increased cyclin E/cdk2 kinase underlying the enhanced proliferation of p14 ARF -deficient cells are not completely understood, these observations suggest that activity promotes S phase entry by phosphorylating Rb and can sustain cell cycle progression by phosphorylating p27kip1, loss of p14 ARF may contribute to the enhanced proliferation of INK4a/ARF-deleted MCL tumors. leading to its degradation in the proteosome. In keeping with this model, most p27kip1 in MCL cells is biochemically associAn important function of p14 ARF is to augment p53 function by antagonizing MDM2 (Sherr and McCormick, 2002) , and loss ated with cyclin D1 (Quintanilla-Martinez et al., 2003) .
Our findings highlight the quantitative sensitivity of the G1/S of this p14 ARF function may contribute to the enhanced proliferation and shorter survival of MCL patients with INK4a/ARF delephase transition to changes in D-type cyclin concentration. This cell cycle transition appears to behave like a rheostat regulated tions. p14 ARF is induced by a variety of oncogenes that promote inappropriate proliferation, leading to a p53-dependent cell cyby cyclin D1 kinase complex levels rather than an on/off switch that is activated when a threshold level of cyclin D1 is achieved cle arrest or apoptosis (Kamijo et al., 1997 (Kamijo et al., , 1998 . In MCL tumors with wild-type INK4a/ARF loci, it is conceivable that some onco-(see Roberts, 1995, 1999 for a complete discussion). In this model, the fraction of cells in the tumor clone that are genic stimuli may activate p14 ARF and constrain proliferation. In this scenario, MCL tumor cells that sustain p14 ARF deletions in G1 phase, and consequently the tumor proliferation rate, would be influenced quantitatively by the abundance of cyclin would have a selective advantage. Our observation that INK4a/ ples, as described previously (Rosenwald et al., 2002) . The complete gene ARF locus deletions and cyclin D1 expression synergize to preexpression data set is available at http://llmpp.nih.gov/MCL. dict the proliferation signature may therefore reflect a cooperation between the p53 pathway and the RB pathway in controlling
Real-time quantitative PCR cell cycle progression. However, we found that some MCL tuTo measure cyclin D1 mRNA expression by real-time quantitative RT-PCR, mors had deletions of both the INK4a/ARF and p53 loci, sugan aliquot of the mRNA used for the microarray experiments was diluted to approximately 0.5 ng/l. 5 l of the diluted mRNA were used for each gesting that p53 deletion may provide additional selective ad-RT-PCR reaction using TaqMan TM reagents and analyzed on an Applied vantages, such as evasion of apoptosis.
Biosystems Thermal Cycler. All samples were run in triplicate, and a probe Though many of the oncogenic events in MCL are designed for the ␤2-microglobulin gene was chosen as a reference. Primers and to promote S phase entry, deletions of the ATM tumor suppresTaqman probes for both ␤2-microglobulin and the coding region of cyclin sor gene appear to play a different role. Roughly one-third of D1 have been described previously (Bijwaard et al., 2001 ).
the MCL tumors in our study had ATM deletions, irrespective
To detect genomic loss of the INK4a/ARF, ATM, and p53 tumor suppresof tumor proliferation rate, INK4a/ARF locus deletional status, sor loci in the tumor specimens, we performed quantitative real-time PCR assays using genomic DNA. The REL locus on chromosome 2p was chosen and cyclin D1 expression and survival. This finding suggests as a reference gene based on comparative genomic hybridization studies that the tumor suppressor role of ATM in MCL is unrelated that showed only infrequent genomic alterations in this chromosomal region mechanistically to G1/S phase checkpoint. ATM is required for in MCL (Bea et al., 1999; Bentz et al., 2000) . Eight control DNA samples activation of p53 in response to DNA damage and abnormal were prepared from peripheral blood mononuclear cells of 5 different healthy telomeres, and during normal immunoglobulin V-D-J recombivolunteers. The ratios of INK4a/ARF locus, ATM, and p53 amplification relanation (Karlseder et al., 1999; Kastan et al., 1992; Perkins et tive to REL amplification were calculated for each control sample. We used these control ratios to establish cutoff ratios that we used to assess tumor al., 2002). However, ATM deletions coincided with p53 deletions DNAs for genomic deletions. For each gene, this cutoff ratio was set as the in several MCL cases, suggesting that loss of these genes may mean ratio minus 3 standard deviation units; the cutoffs for the INK4a/ serve distinct functions in the pathogenesis of some MCLs.
ARF locus/REL, ATM/REL, and p53/REL ratios were 0.67, 0.72, and 0.7, Finally, our data provide quantitative insights into the potenrespectively. A tumor DNA sample that yielded an amplification ratio below tial of cell cycle inhibitors in the therapy of MCL. Although cell the cutoff ratio for a particular tumor suppressor gene was considered to cycle inhibitors would not necessarily be curative in MCL, it is have a genomic deletion of that gene. We used previously described primer and TaqMan probe sets for the possible that they could alter its natural history, yielding a INK4a/ARF locus that were situated in exonic regions that are shared by chronic lymphoproliferative disease that could be managed tively, it is possible that inhibitors that target the G1/S checkpoint by disrupting cyclin D1/cdk4(6) complexes could be ad-
Statistical methods
ministered chronically, and might turn MCL into a clinically
Bayesian formulation of a discrimator between two manageable disease.
lymphoma subtypes
The method we used to formulate our predictor of MCL was based on a Experimental procedures variation of the compound covariate predictor (Radmacher et al., 2002) . Although our complete method involved the distinction between MCL and Patients several different classes of samples, we begin by describing a general Tumor biopsies from 101 untreated patients with no history of a previous method for estimating the probability that a given sample is in one of two lymphoma were included in the present study, according to a protocol groups, based on data from a fixed training set. approved by the National Cancer Institute institutional review board. Tumor
We begin with a gene selection step. For each gene in our training set, histology was reviewed by a panel of 8 hematopathologists, and 92 biopsy we calculated the t statistic for the difference in the expression of that gene specimens were classified as mantle cell lymphoma, based on established between the two groups. After our data set was so reduced to include morphologic and immunophenotypic criteria (Jaffe et al., 2001 ). All of these only unique genes, we choose the k genes with most statically significant t 92 cases showed overexpression of cyclin D1 mRNA by a quantitative RTstatistics to use in our predictor. In order to avoid redundancy, when multiple PCR assay and, in most cases, immunohistochemistry demonstrated overspots for a given gene were found on the array, we only considered the expression of cyclin D1 also on the protein level. In the remaining nine spot that gave the most statistically significant t statistic. This resulted in a lymphoma specimens, the morphology and immunophenotype of the tumor list of k unique genes that were variably expressed between the two groups. cells were consistent with the diagnosis of MCL, but there was no evidence
The method we used to choose k will be discussed later. of the t(11;14) translocation or cyclin D1 protein expression. All nine of these Given a training sample, the standard 2-group compound covariate cases were negative for cyclin D1 mRNA expression by quantitative RTpredictor associates with each sample a compound covariate score (CCS) PCR. Only data obtained from the 92 patients with cyclin D1-positive MCL given by were used to create the gene expression-based predictor of survival. Among
t j X j , these 92 patients, 72 were male and 19 female (no information was available on one patient), the median age at diagnosis was 61.5 years (range 38 to 92.5 years) and median survival was 2.8 years. 84 patients received multiagent where t j is the t statistic for the two-group comparison of the log ratios for chemotherapy as needed symptomatically, 6 received no treatment, and no gene j in the training set, and X j is the log ratio for gene j of the sample. information on treatment was available in 2 patients. This sum is taken over the k most significant t statistics. . value from the log rank test was used. A Cox model was also fit to the combination of the cyclin D1 coding region expression and an indicator of Strictly speaking, there should be additional terms indicating the general INK4a/ARF deletion. For the purpose of displaying survival curves in Figure  prevalence of group 1 and group 2 in the population at large, but since we 5C, the samples were ranked according to this model and divided into make no claims as to the representative nature of our patient sample, we quartiles. A likelihood ratio p value was reported from the combined model. eliminated these terms, inherently assuming that Group 1 and Group 2 were A Spearman rank correlation test was used to indicate the association equally prevalent.
between proliferation and expression of the cyclin D1 coding region. When Since CCS(X) is the linear combination of multiple measurements, it is not determining differences between the high/low cyclin D1 3Ј UTR in proliferaunreasonable to assume that the distribution of CCS(X) within each subgroup tion and cyclin D1 coding region expression, the p value from a 2-sided t will be approximately normal. So if we let M 1 and M 2 be the sample means test was reported. t tests were also used to determine the extent to which of CCS(X) within group 1 and group 2 of the training set, and s 1 2 and s 2 2 genes were differentially expressed between MCL and each other lymphoma the respected sample variances, we can make the following estimate:
subtypes. An ANOVA model was used to determine the extent to which INK4a/ARF locus deletion and cyclin D1 coding region expression added P(Y in Group 1) ϭ constructively in their association with proliferation.
In forming the predictor of survival, we used those genes that were
found in the proliferation signature, were associated with poor prognosis in the training set (p Ͻ 0.001 according to a Wald test), and had larger variance where φ represents the normal density.
across the samples of the training set than 2/3 of the genes. When multiple Lymphochip microarray features representing the same gene were found to satisfy these conditions, only the feature that was most significantly associ-φ(x; , 2 ) ϭ 1
√2
e Ϫ(xϪ)/2 2 . ated with survival on the training set was used. No survival information from the validation set was used to generate the gene list. The expression data For ease in notation we write for each of these genes were mean centered across all samples, and the proliferation signature average for a given sample was computed as the P 1 (Y) ϵ P(Y in Group 1).
average of these mean centered observations. Missing values for genes were excluded in taking this average.
Formulation of a gene expression-based MCL diagnostic test
We began by equally dividing the gene expression data from MCL and other Acknowledgments lymphoma samples into a training set and a validation set. The training set consisted of 46 MCL samples, 42 ABC samples, 67 GCB samples, and 11
We are very grateful to Chuck Sherr for helpful discussions and suggestions. SLL samples. The validation set was similarly composed, but had one fewer ABC sample. Since our goal was to determine which genes other than cyclin D1 were related to MCL, we excluded all cyclin D1 clones from this analysis.
In generating an MCL versus non-MCL predictor, a simple two class within the non-MCL subset. Instead, we generated 3 separate 2-group predictors: MCL versus ABC, MCL versus GCB, and MCL versus SLL. References Each model was trained only on those elements of the training set that matched the model (i.e., only the MCL and GCB cases were used to train the MCL versus GCB model.) Since a priori the optimal value of k, the number Alizadeh, A., Eisen, M., Davis, R.E., Ma, C., Sabet, H., Tran, T., Powell, J., Yang, L., Marti, G., Moore, T., et al. (1999) . The Lymphochip: A specialized of genes included in a given predictor, was unknown, we used leave-onecDNA microarray for the genomic-scale analysis of gene expression in norout crossvalidation (Hills, 1966) to optimize this value. According to leavemal and malignant lymphocytes. Cold Spring Harb. Symp. Quant. Biol. 64, one-out crossvalidation, one sample at a time is removed from the training 71-78. set, and the remaining samples are used to form a predictor, which is applied to the removed sample. This is repeated each time, reselecting genes and Argatoff, L.H., Connors, J.M., Klasa, R.J., Horsman, D.E., and Gascoyne, reformulating the predictor, until each sample has been left out once. This R.D. (1997) . Mantle cell lymphoma: a clinicopathologic study of 80 cases. method was repeated for different values of k, and we choose the value Blood 89, 2067-2078. that gave us the lowest total leave-one-out error probability for a given Barista, I., Romaguera, J.E., and Cabanillas, F. Bea, S., Ribas, M., Hernandez, J.M., Bosch, F., Pinyol, M., Hernandez, L., Where the probabilities are computed based on a training set of all samples Garcia, J.L., Flores, T., Gonzalez, M., Lopez-Guillermo, A., et al. (1999) . except Y. This optimization resulted in k ϭ 9 for the GCB versus MCL Increased number of chromosomal imbalances and high-level DNA amplifipredictor, k ϭ 20 genes for ABC versus MCL predictor, and k ϭ 85 for the cations in mantle cell lymphoma are associated with blastoid variants. Blood SLL versus MCL predictor.
93, 4365-4374. Using these k values, we now used the entire training set to generate the Bea, S., Tort, F., Pinyol, M., Puig, X., Hernandez, L., Hernandez, S., Fernanthree predictors and applied it to the training set. We defined a patient, Y, dez, P.L., van Lohuizen, M., Colomer, D., and Campo, E. (2001) . BMI-1 as MCL only if P MCL (Y ) Ͼ 0.9 for all three predictors. This resulted in only gene amplification and overexpression in hematological malignancies occur one misclassification, in which an MCL predictor had P ABC (Y ) Ͼ 0.9. Incidenmainly in mantle cell lymphomas. Cancer Res. 61, 2409-2412. tally, we also observed that all of the non-MCL patients were correctly assigned by their respective predictors with p Ͼ 0.9. (i.e., P GCB [Y] Ͼ 0.9 for Bentz, M., Plesch, A., Bullinger, L., Stilgenbauer, S., Ott, G., Muller-Hermelink, H.K., Baudis, M., Barth, T.F., Moller, P., Lichter, P., and Dohner, H. all Y in GCB on the validation set, etc.).
